Trailing Twelve Months Revenue Growth: Jazz Pharmaceuticals Corp (JAZZ)

Graphic logo of Jazz Pharmaceuticals Corp (JAZZ)

Jazz Pharmaceuticals dominates the narcolepsy and rare tumor treatment niche thanks to FDA protection. Xywav and Epidiolex are driving short-term momentum, as confirmed by the 12-month YoY sales dynamics on the GURU.Markets terminal chart, where the value 13.60 serves as the baseline indicator. Steady capital inflows and high profitability within the neurobiology segment guarantee business resilience.

Jazz Pharmaceuticals (JAZZ): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/18/2026

jazzpharma.com (JAZZ) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Fundamental company valuation:Jazz Pharmaceuticals, JAZZ
Product sample of Jazz Pharmaceuticals

Jazz Pharmaceuticals revenues are based on the sale of high-cost drugs for the treatment of narcolepsy and epilepsy through government insurance funds. This trailing twelve-month (TTM) revenue chart allows for the real-time tracking of rolling revenue dynamics over four quarters. This metric measures the pace of business expansion, where local dips are often offset by internal cost optimization. For the long-term investor, this indicator serves as a signal of systemic shifts in the operating model.